A randomized, placebo-controlled trial of latrepirdine in Huntington disease. - Wikidata - awgldk - TriplyDB

A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

http://www.wikidata.org/entity/Q30411257

about

The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditions Treatment of Huntington's disease.The rise and fall of Dimebon.Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease Ruthenium-catalyzed γ-carbolinium ion formation from aryl azides; synthesis of dimebolin.Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease.The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice.Video Rating in Neurodegenerative Disease Clinical Trials: The Experience of PRION-1.Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice.Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain.Intermediate CAG Repeats in Huntington's Disease: Analysis of COHORT.Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model.Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer's disease.5-hydroxytryptamine subtype 6 receptor modulators: a patent survey.The clinical and genetic features of Huntington disease.Pharmacologic approaches to the treatment of Huntington's disease.Mitochondrial dysfunction--a pharmacological target in Alzheimer's disease.Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases The most appropriate primary outcomes to design clinical trials on Huntington's disease: meta-analyses of cohort studies and randomized placebo-controlled trials.Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium.Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice.Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts.Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.The gramine route to pyrido[4,3-b]indol-3-ones - identification of a new cytotoxic lead.Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast.The impact of oculomotor functioning on neuropsychological performance in Huntington disease.Rating scales for cognition in Huntington's disease: Critique and recommendations.Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations

P2860

Q22306292-BF2B63F5-08ED-4B9C-B476-F0F10689BE15 Q26781560-D67096BE-E375-4F6E-918A-7EF3175B1C51 Q26782004-AD4699F7-74F4-49F4-9E12-6E71F6CBF070 Q34146766-E19473D8-3241-4178-BAF8-02FA6A08590C Q34547558-48877E71-1ACC-4901-9E51-8DC3A402CCA6 Q34557710-49A0C218-7652-4391-A9FB-852748E69F93 Q34989553-2F82E43F-9C7D-4A1A-9E57-523099E82535 Q34994270-8A970ED6-A68E-47E1-AF48-D1725FBD9ECC Q35376045-491610C7-DE4D-4C32-A566-6F21DED62A0D Q35645271-DC22D46C-FD4D-4B4D-8C19-F6A69E63E4BB Q35957568-CC406BEF-A11C-44D1-9400-286EECB11F8B Q36213835-B5996CFD-1078-4D96-83CD-41D58AE3556D Q36304050-76BB8B0C-8CF1-4BB1-BA39-8F75EBF9D8C3 Q36469322-7E80FB2A-A22F-4101-B507-DC926B5EB3FE Q36603022-1AC2167C-0242-40B9-B208-144379D146B5 Q36763793-4C5EA499-9A12-40E9-B412-A4BFCD06180B Q37736181-33B35784-15F0-48C1-8E98-B644EA73B102 Q37780550-C57893E8-B369-4C93-A754-3638E679FD6B Q37798079-FD266578-D20E-4A5D-9B59-565DC031491E Q37945478-EA92BC78-E897-469F-AB5C-7E2DC438639D Q38007107-EC59F055-B909-4AE1-979F-CDED27933E03 Q38168475-CCC7AC04-4E76-4EC6-98D5-C8C42ED4AE4E Q38202178-E2E55A87-33A9-46CA-B2E9-79354C340CA6 Q38603960-3E984937-46CA-4282-8D96-B7639B4370D0 Q38624671-F77581D1-A4FA-45CC-BA15-4C25F00F7921 Q38792714-41E2FED0-AEAD-4CDF-B515-99052D08CFD7 Q39035495-EE75951B-0949-4AE3-A165-54890570C8A0 Q42071456-42360F4D-665E-470E-A84F-9802325A56F5 Q42115187-8B8071CE-5B0F-47BF-AEEB-07530C7CF3D2 Q45292458-8B03E813-7989-45D6-84A5-46C61EBE29DE Q47219147-31B81BA9-71B0-4599-8BCD-D950AB9DE697 Q58574520-7FDD26CE-B43B-441E-ABA4-73D475325B5E

P2860

A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

http://www.wikidata.org/entity/Q30411257

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

@ast

A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

@en

type

label

A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

@ast

A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

@en

prefLabel

A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

@ast

A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

@en

P1433

Q30411257-D5C62F63-652D-4BEF-8788-2079723FA85E

P1476

Q30411257-16109803-62EA-4FC7-92A2-AD8DD2B6F5DE

P2093

Q30411257-002574A2-42E8-4AB4-B40D-21CDD93E0DCD

Q30411257-04E8B584-A3B2-47F2-BA1E-7AA3B3EF5FDB

Q30411257-278CE9D3-CDDE-4A43-803B-2382B579DB97

Q30411257-28E2C544-A618-43D9-9D6B-9362CF45897F

Q30411257-36A48FF5-D9EF-4F41-A65C-06A464E4D265

Q30411257-63C1D8F4-2015-4C03-BFA5-B11ECBEC2B1A

Q30411257-67A05244-D174-43D4-B3CD-F6ECFCCEB201

Q30411257-69AE8EE9-CAB9-449D-9D8D-BE00F3E75FD3

Q30411257-71F36AC5-B871-4501-BEDC-8DE4054628A6

Q30411257-9589EA74-5CFA-4CC0-AD1C-5BA2435CAEC6

P2860

Q30411257-37363FA5-2FEE-48F7-A48E-9ED305BA18AE

Q30411257-37F613FD-51D4-477B-BE2C-906CDE66F4AC

Q30411257-41710FD4-F831-4DBD-8DC8-F6C43D0CC2CB

Q30411257-55264171-0075-42E3-A0F2-117EC1AB3791

Q30411257-7637B23D-0368-4A97-9CA6-1DB65B67447A

Q30411257-88E7581B-63F3-4DAB-B16A-90E2FE4F07E7

Q30411257-8D290F27-311B-4728-9129-D3820F0819D5

Q30411257-B3A920C2-BFB6-4BF7-932C-15904B780494

Q30411257-BAB30CD1-7E72-491E-A614-F1EE0DF3AE74

P304

Q30411257-47EF248E-A025-4080-A92D-04EFE9E8E19F

P31

Q30411257-D0E18127-422E-48B3-8678-280DA6BD783C

P356

Q30411257-2A2115C3-EE12-4C06-A3CE-3AC02D82244E

P433

Q30411257-E787AE49-969B-4706-8732-3327ACCB3506

P478

Q30411257-8CE3B6A9-8250-4543-80ED-6CE723061EA4

P50

Q30411257-940C1E7B-BE8E-4788-8444-42BFF7B9AF85

Q30411257-9805FB67-E1DD-4587-9A06-1532F62FC750

Q30411257-98ECC15D-DD11-4C59-8AA9-5DF48EEC69E7

Q30411257-AD51E87D-5BF9-4CEB-BE3A-F1B289ECE621

P577

Q30411257-56552346-C47F-46F4-AE70-DDCAC21C7945

P698

Q30411257-94055380-BE43-4730-BEA1-A870BFD0BE33

P921

Q30411257-0A1BE669-A292-4740-A1BF-634220022EA5

Q30411257-9AC5BFBE-0E20-49D7-85CC-67F4CBFD4787

P932

Q30411257-6BCBF78C-15A6-4AD3-BD0B-52522890A5FE

P356

ARCHNEUROL.2009.334

P1433

P1476

A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

@en

P2093

Andrew Feigin

http://www.w3.org/2001/XMLSchema#string

Bernard Ravina

http://www.w3.org/2001/XMLSchema#string

Dimebon in Subjects with Hunti ...... of the Huntington Study Group

http://www.w3.org/2001/XMLSchema#string

E Ray Dorsey

http://www.w3.org/2001/XMLSchema#string

Elise Kayson

http://www.w3.org/2001/XMLSchema#string

Francis Walker

http://www.w3.org/2001/XMLSchema#string

Huntington Disease Study Group DIMOND Investigators

http://www.w3.org/2001/XMLSchema#string

Jody Corey-Bloom

http://www.w3.org/2001/XMLSchema#string

Karen Hodgeman

http://www.w3.org/2001/XMLSchema#string

Karen Rabinowitz

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease.

Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.

In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease.

The proteasomal inhibition model of Parkinson's disease: "Boon or bust"?

A new rating scale for Alzheimer's disease.

Unified Huntington's disease rating scale: Reliability and consistency

P304

154-160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHNEUROL.2009.334

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

Juan Sanchez-Ramos

Jody Corey-Bloom

Stewart A Factor

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20142523

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

4134015

http://www.w3.org/2001/XMLSchema#string